Skip to main content

Advertisement

SpringerLink
Log in

Effects of chemotherapy on patients with recurrent cervical cancer previously treated with concurrent chemoradiotherapy: a retrospective multicenter survey in Japan

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Predictive factors of the efficacy of chemotherapy for Japanese patients with recurrent cervical cancer who have been previously treated with concurrent chemoradiotherapy (CCRT) are currently unknown, and hence we aimed to investigate this.

Methods

We retrospectively studied the prognostic outcomes of patients with recurrent cervical cancer treated with CCRT between 2002 and 2010 at four medical facilities.

Results

A total of 64 patients were included in this study. Forty-two patients received definitive CCRT and 22 patients received postoperative adjuvant CCRT, with 55 receiving platinum-based combination chemotherapy and nine receiving single-agent chemotherapy. The overall response rate (ORR) was 12.5 %, with one complete response. The median survival period was 12 months. The ORR and overall survival rate did not differ significantly according to recurrence site, post-CCRT interval, or chemotherapy regimen.

Conclusion

None of the factors analyzed in this study were identified as positive predictive factors for the efficacy of chemotherapy in patients with recurrent cervical cancer after CCRT. Based on the results of previous studies, in order to improve long-term prognosis in recurrent cases, adjuvant chemotherapy should be considered as a potential treatment option for selected patients, especially as postoperative adjuvant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Peters WA 3rd, Liu PY, Barrett RJ et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606–1613

    CAS  PubMed  Google Scholar 

  2. Rose PG (2000) Chemoradiotherapy: the new standard care for invasive cervical cancer. Drugs 60:1239–1244

    Article  CAS  PubMed  Google Scholar 

  3. Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143

    Article  CAS  PubMed  Google Scholar 

  4. Rose PG, Bundy BN, Watkins EB et al (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153

    Article  CAS  PubMed  Google Scholar 

  5. Whitney CW, Sause W, Bundy BN et al (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 17:1339–1348

    CAS  PubMed  Google Scholar 

  6. Green JA, Kirwan JM, Tierney JF et al (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358:781–786

    Article  CAS  PubMed  Google Scholar 

  7. Lukka H, Hirte H, Fyles A et al (2002) Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer—a meta-analysis. Clin Oncol 14:203–212

    Article  CAS  Google Scholar 

  8. (2014) National comprehensive cancer network guidelines for treatment of cancer. http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Retrieved March 13, 2014

  9. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  PubMed  Google Scholar 

  10. Omura GA, Blessing JA, Vaccarello L et al (1997) Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15:165–171

    CAS  PubMed  Google Scholar 

  11. Bloss JD, Blessing JA, Behrens BC et al (2002) Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 20:1832–1837

    Article  CAS  PubMed  Google Scholar 

  12. Moore DH, Blessing JA, McQuellon RP et al (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22:3113–3119

    Article  CAS  PubMed  Google Scholar 

  13. Long HJ 3rd, Bundy BN, Grendys EC Jr et al (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4626–4633

    Article  CAS  PubMed  Google Scholar 

  14. Teshima T, Inoue T, Ikeda H et al (1993) High-dose rate and low-dose rate intracavitary radiation therapy for cancer of the uterine cervix. Final results of Osaka University Hospital. Cancer 72:2409–2414

    Article  CAS  PubMed  Google Scholar 

  15. Watanabe Y, Nakai H, Shimaoka M et al (2006) Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. Int J Clin Oncol 11:309–313

    Article  CAS  PubMed  Google Scholar 

  16. Ikushima H, Osaki K, Furutani S et al (2006) Chemoradiation therapy for cervical cancer: toxicity of concurrent weekly cisplatin. Radiat Med 24:115–121

    Article  CAS  PubMed  Google Scholar 

  17. Toita T, Kitagawa R, Hamano T et al (2012) Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066). Int J Gynecol Cancer 22:1420–1426

    Article  PubMed  Google Scholar 

  18. Monk BJ, Sill MW, McMeekin DS et al (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:4649–4655

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Moore DH, Tian C, Monk BJ et al (2010) Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 116:44–49

    Article  CAS  PubMed  Google Scholar 

  20. Shimada M, Nishimura R, Hatae M et al (2013) Comparison of adjuvant chemotherapy and radiotherapy in patients with cervical adenocarcinoma of the uterus after radical hysterectomy: SGSG/TGCU Intergroup surveillance. Eur J Gynaecol Oncol 34:425–428

    CAS  PubMed  Google Scholar 

  21. Li S, Hu T, Chen Y et al (2013) Adjuvant chemotherapy, a valuable alternative option in selected patietns with cervical cancer. PLoS One. doi:10.1371/journal.pone.0073837

    Google Scholar 

  22. Lee TY, Jeung YJ, Lee CJ et al (2013) Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer. Obstet Gynecol Sci 56:15–21

    Article  PubMed Central  PubMed  Google Scholar 

  23. Takeshima N, Umayahara K, Fujiwara K et al (2006) Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer. Gynecol Oncol 103:618–622

    Article  CAS  PubMed  Google Scholar 

  24. Pignata S, Frezza P, Tramontana S et al (2000) Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri. Ann Oncol 11:455–459

    Article  CAS  PubMed  Google Scholar 

  25. Rao GC, Rogers P, Drake RD et al (2005) Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gyncol Oncol 96:168–172

    Article  CAS  Google Scholar 

  26. Sehouli J, Runnebaum IB, Fotopoulou C et al (2012) A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Ann Oncol 23:2259–2264

    Article  CAS  PubMed  Google Scholar 

  27. Tewari KS, Sill MW, Long HJ III et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734–743

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Schefter TE, Winter K, Kwon JS et al (2011) A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys 83:1179–1184

    Article  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Tohoku Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

    Hideki Tokunaga, Satoru Nagase, Nobuo Yaegashi & Yoh Watanabe

  2. Department of Gynecology, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan

    Toru Nakanishi

  3. Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

    Takashi Iwata & Daisuke Aoki

  4. Department of Gynecology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan

    Toshiaki Saito

  5. Department of Clinical Research Network, Clinical Research Innovation and Education Center, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

    Fumiaki Takahashi & Yoh Watanabe

Authors
  1. Hideki Tokunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toru Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daisuke Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshiaki Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Satoru Nagase
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fumiaki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobuo Yaegashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoh Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideki Tokunaga.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tokunaga, H., Nakanishi, T., Iwata, T. et al. Effects of chemotherapy on patients with recurrent cervical cancer previously treated with concurrent chemoradiotherapy: a retrospective multicenter survey in Japan. Int J Clin Oncol 20, 561–565 (2015). https://doi.org/10.1007/s10147-014-0728-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-014-0728-9

Keywords

Search

Navigation